Project
[ Redacted ]
A redacted sample of a typical HALO™ deliverable for a mid-market PE healthcare services target. All target, sponsor, peer, and quantification detail has been removed for open distribution.
This document is a redacted reproduction of a Telesto HALO™ Brand Due Diligence engagement delivered to a mid-market private equity sponsor. Target name, sponsor name, peer set, dollar quantifications, primary-research quotations, and source attributions have been removed. The structure, methodology, scoring framework, and analytical depth shown here are representative of a live client deliverable.
HALO™ scoring across all five pillars indicates the target's brand position is neither best-in-class nor distressed, but is on a measurable downward velocity that has not yet materialized in volume or revenue. The window to intervene before that translation is approximately 6–12 months.
Each pillar is scored 1 (severe) to 5 (best-in-class) against a calibration set of ~40 mid-market healthcare services assets in Telesto's HALO™ reference panel. Scoring is anchored to the underwriting line item the pillar moves — not to a generic brand-strength index.
Composite is a weighted blend of the five pillars, with weights calibrated to the underwriting model line items each pillar moves. Weights and sensitivity ranges are documented in Appendix B.
Primary intelligence with referring physicians, case managers, and payer network leads. Tests prompted and unprompted recall, perceived clinical quality, and likelihood-to-refer against two named regional peers.
| Recall Metric | vs. Peer A | vs. Peer B | vs. Peer C |
|---|---|---|---|
| Unprompted recall, legacy referrer base | [ redacted ] | [ redacted ] | [ redacted ] |
| Unprompted recall, newer referring physicians | [ redacted ] | [ redacted ] | [ redacted ] |
| Perceived clinical-quality rank | [ redacted ] | [ redacted ] | [ redacted ] |
| Likelihood-to-refer (top-2-box) | [ redacted ] | [ redacted ] | [ redacted ] |
| Payer-network lead recall, recent expansion markets | [ redacted ] | [ redacted ] | [ redacted ] |
n = 47 referrer interviews, 12 payer-network interviews · conducted across 4 catchment markets · sample composition methodology in Appendix D.
| Line Item | HALO™ Pillar(s) | Value at Risk |
|---|---|---|
| Organic-discovery revenue exposure (5-year hold) | Pillars 1 & 2 | [ redacted ] |
| Clinician acquisition cost delta (annualized, steady state) | Pillar 4 | [ redacted ] |
| Roll-up brand integration dyssynergy (first 18 months) | Pillar 5 | [ redacted ] |
| Net-new referral capture compression | Pillar 3 | [ redacted ] |
| Total brand-driven enterprise value at risk | Composite | $ [ redacted ] M |
Quantification model assumptions, sensitivity ranges, and reconciliation to commercial DD revenue model in Appendix C. Values are point estimates; full report includes low / base / high cases.
Sequenced post-close interventions to neutralize the brand-driven value at risk identified above. Each item maps to the pillar(s) it addresses and the line item it moves.